OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SUN.CM55

Sunshine Holdings PLC

Drug RetailersVerified

Sunshine Holdings PLC maintains a relatively strong liquidity position, with a current ratio of 2.12, indicating that it has more than twice as many current assets as current liabilities. However, the company's net cash position is negative after subtracting total debt, which suggests that its cash and equivalents are insufficient to cover its long-term obligations. The company's liquidity risk is assessed as medium, reflecting the potential strain on its short-term financial flexibility. In terms of profitability, the company's return on equity (ROE) of 20.89% and return on assets (ROA) of 8.8% are strong indicators of efficient capital utilization and asset management. These metrics suggest that the company is generating solid returns for its shareholders and effectively deploying its assets to generate profit. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the business operates within the drug retailing industry, which is typically less sensitive to economic cycles. The company's exposure to this sector implies a relatively stable revenue stream, though it may face challenges from regulatory changes or competitive pressures. Looking ahead, the company's growth trajectory is not explicitly outlined in the available data, but its operating income of $9.28 billion and net income of $4.24 billion suggest a strong financial foundation. The company's capital expenditures of -$1.26 billion indicate a net outflow from investing activities, which may reflect ongoing investments in infrastructure or expansion. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively. Recent events, such as filings and transcripts, are not detailed in the available data, but the company's financial performance and risk profile suggest a stable and well-managed business.

30-day price · SUN.CM+0.20 (+0.6%)
Low$29.60High$33.60Close$31.50As of25 May, 00:00 UTC
Profile
CompanySunshine Holdings PLC
TickerSUN.CM
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. Sunshine Holdings PLC operates in the drug retailing industry, generating revenue primarily through the sale of prescription and over-the-counter medications, health and wellness products, and related services.

Classification. Sunshine Holdings PLC is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry, with a confidence level of 0.92.

Sunshine Holdings PLC maintains a relatively strong liquidity position, with a current ratio of 2.12, indicating that it has more than twice as many current assets as current liabilities. However, the company's net cash position is negative after subtracting total debt, which suggests that its cash and equivalents are insufficient to cover its long-term obligations. The company's liquidity risk is assessed as medium, reflecting the potential strain on its short-term financial flexibility. In terms of profitability, the company's return on equity (ROE) of 20.89% and return on assets (ROA) of 8.8% are strong indicators of efficient capital utilization and asset management. These metrics suggest that the company is generating solid returns for its shareholders and effectively deploying its assets to generate profit. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the business operates within the drug retailing industry, which is typically less sensitive to economic cycles. The company's exposure to this sector implies a relatively stable revenue stream, though it may face challenges from regulatory changes or competitive pressures. Looking ahead, the company's growth trajectory is not explicitly outlined in the available data, but its operating income of $9.28 billion and net income of $4.24 billion suggest a strong financial foundation. The company's capital expenditures of -$1.26 billion indicate a net outflow from investing activities, which may reflect ongoing investments in infrastructure or expansion. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively. Recent events, such as filings and transcripts, are not detailed in the available data, but the company's financial performance and risk profile suggest a stable and well-managed business.
Key takeaways
  • Sunshine Holdings PLC has a strong return on equity (20.89%) and return on assets (8.8%), indicating efficient capital and asset utilization.
  • The company's liquidity position is medium risk, with a current ratio of 2.12 but a negative net cash position after subtracting total debt.
  • The company operates in the drug retailing industry, which is typically less sensitive to economic cycles, providing a relatively stable revenue stream.
  • The company's capital expenditures suggest ongoing investment in infrastructure or expansion, though the exact nature of these investments is not disclosed.
  • The company's dilution risk is low, and no significant dilution sources are identified in the available data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyLKR
Revenue$59.28B
Gross profit$17.85B
Operating income$9.28B
Net income$4.24B
R&D
SG&A
D&A
SBC
Operating cash flow$5.78B
CapEx-$1.26B
Free cash flow$1.92B
Total assets$48.15B
Total liabilities$27.85B
Total equity$20.30B
Cash & equivalents$5.88B
Long-term debt$7.62B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$20.30B
Net cash-$1.74B
Current ratio2.1
Debt/Equity0.4
ROA8.8%
ROE20.9%
Cash conversion1.4%
CapEx/Revenue-2.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricSUN.CMActivity
Op margin15.7%3.1% medp25 1.2% · p75 6.8%top quartile
Net margin7.2%2.0% medp25 0.7% · p75 4.1%top quartile
Gross margin30.1%26.1% medp25 17.2% · p75 32.0%above median
CapEx / revenue-2.1%-2.5% medp25 -4.6% · p75 -1.4%above median
Debt / equity38.0%56.0% medp25 16.8% · p75 121.1%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 21:25 UTC#f2cb6da6
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 14:47 UTCJob: f39e15a8